Short Interest in MetaVia Inc. (NASDAQ:MTVA) Declines By 61.8%

MetaVia Inc. (NASDAQ:MTVA) saw a large decline in short interest during the month of January. As of January 30th, there was short interest totaling 62,409 shares, a decline of 61.8% from the January 15th total of 163,195 shares. Currently, 2.9% of the shares of the company are sold short. Based on an average daily trading volume, of 328,523 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 328,523 shares, the days-to-cover ratio is currently 0.2 days. Currently, 2.9% of the shares of the company are sold short.

Analyst Ratings Changes

A number of research firms recently issued reports on MTVA. HC Wainwright raised their price objective on shares of MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Finally, Wall Street Zen cut shares of MetaVia from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, MetaVia presently has an average rating of “Hold” and a consensus price target of $36.50.

MetaVia Price Performance

NASDAQ MTVA remained flat at $1.66 during trading on Thursday. 103,754 shares of the company’s stock traded hands, compared to its average volume of 291,426. The stock has a market capitalization of $3.65 million, a PE ratio of -0.20 and a beta of 0.27. MetaVia has a 1-year low of $1.61 and a 1-year high of $23.10. The business’s 50-day simple moving average is $6.05 and its 200 day simple moving average is $7.99.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC grew its stake in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the period. SG Americas Securities LLC owned 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. 1.37% of the stock is owned by institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.